Explore Video

View comprehensive coverage of Breast Cancer from ESMO 2022

There are no randomized clinical trials addressing the continued use of Trastuzumab for Her2 positive MBC patients in prolonged remission and has become important and relevant clinical question.

Bone marrow examination-based diagnosis of MDS with either biopsy or aspirate remains standard of care but is associated with pain, bleeding, difficulty to use the same in elderly patients and hIgh interobserver variability.

Endocrine therapy is the mainstay in the management of patients with Hormone receptor positive (ER+ve) Metastatic Breast Cancer. Tumor progression in ER+ve MBC could be attributed to genomic alterations such as ESR mutations.

Combination of CDK4/6 inhibitors & aromatase inhibitor is recommended for frontline treatment of Hormone receptor positive (ER+ve) Metastatic Breast Cancer. Patients eventually develop disease progression which might be attributed to ESR1 mutations.

Dr Scott Soefje, PharmD, Mayo Clinic
Provides a perspective “Quality Management Systems in Pharmacy Practice”.

The landscape of HR+ve/HER2-negative metastatic breast cancer (MBC) has evolved significantly with the introduction of newer treatment options such as CDK4/6 inhibitors, PI3K inhibitors, and selective estrogen receptor down regulators.

Effective management of Palbociclib's side effects involves regular monitoring of blood counts to detect neutropenia, along with managing symptoms like fatigue, nausea, and infections.

Whole Genome Sequencing (Short)
Whole Genome Sequencing is new tool for precision medicine in metastatic castration

Summary of Key Abstracts from SABCS 2022